ARR by 52% vs interferon beta-1a. 7 In post hoc comparisons of DMF vs glatiramer-acetate differences were not significant except for new and/or enlarging T2-weighted hyperintense lesions. 4 No difference in ARR between teriflunomide and IFNβ-1a was seen in TENERE. 8 Studies matching the clinical efficacy provided conflicting results. [9] [10] [11] [12] [13] [14] [15] These discrepancies ask for further investigations to confirm or rebut the published findings.
The objective of our study was, first, to compare the efficacy of fingolimod, DMF or teriflunomide and, second, to analyse the probability for stopping, pausing or switching (treatment interruption)
either therapy in a nationwide observational cohort using prospectively collected data from a real-life setting.
| MATERIAL S AND ME THODS

| Data collection
The Austrian MS Treatment Registry (AMSTR), 16 AMSTR documents anonymous baseline data, including MS onset and duration, relapses in the prior 12 months, EDSS, gross MRI activity and previous disease-modifying therapies (DMT). Follow-up data (relapses, EDSS, adverse events [AE's], change or discontinuation of treatment) are required to be documented every 3-6 months, mean follow-up 4 months for fingolimod, 4 months for DMF and 3.9 months for teriflunomide. Each relapse had to be confirmed by a neurologist at the MS centre and documented in the AMSTR.
Documentation required relapse onset, EDSS and use/dose of iv methylprednisolone treatment. Besides the fact that applying the AMSTR is mandatory for reimbursement, a special quality-related feature of the AMSTR is an external and independent data monitoring to improve data management in terms of completeness and plausibility of documented data.
In 2011, the European Medicines Agency (EMA) approved fingolimod along the same indication criteria as natalizumab.
Reimbursement for fingolimod in Austria adheres to this approval.
Thus, fingolimod-treated patients in Austria had to have either at least one relapse in the prior 12 months despite treatment with interferon beta or glatiramer-acetate and at least 9 T2 lesions or at least one Gadolinium-enhancing lesion on recent brain MRI ("indication A"), or two or more severe relapses in the preceding treatment-naïve 12 months and one or more Gadolinium-enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI ("indication B").
In 2013, teriflunomide and in 2014, DMF were approved by the EMA with the indication for the treatment of adult patients with RRMS.
We investigated a total cohort of 1165 patients, who started treatment with fingolimod, DMF or teriflunomide in the AMSTR at any time since 2014. The coverage of the AMSTR for the three oral agents is approximately 70% of the total prescription in Austria. For the purpose of this study, we analysed the data of these patients in two separate cohorts. The first cohort stayed on therapy for at least 12 months (12m cohort), and this group was analysed for comparing the efficacy. The second cohort was the total cohort, defined with at least one follow-up visit, also including the 12m cohort. This group was analysed for the frequency, cause and risk of interruption (total cohort).
The primary outcome measure was the ARR under treatment with fingolimod, DMF or teriflunomide over 1 year after initiation of therapy. Relapses were defined as new or worsening neurological symptoms lasting for at least 24 hours in the absence of fever.
Further outcome measures were the total number of relapses, EDSS progression or regression confirmed after 3 and 6 months, and 
| Statistical methods
All effects estimated in comparing treatment groups were average treatment effects (ATE). To control the bias for non-randomised assignment to the treatment groups, we used inverse probability weighting. As we compared three groups, we used the estimation of multinomial propensity scores as described by McCaffrey. Cox proportional hazards models were used analysing EDSS progression and regression confirmed after 3 and 6 months, and the relapse hazard in the 12 months observation period.
Cox proportional hazards models were also used analysing treatment interruptions in the patient cohort with at least one follow-up visit.
All models included treatment as categorical factor and inverse multinomial propensity scores as weights regarding the survey character of the study.
For all Cox models, the proportional hazards assumption had been verified by non-significant deviations from the proportional hazards assumption using chi-square test.
As statistical programmes, we used IBM SPSS Statistics for 
| RE SULTS
The 12 months continuous treatment cohort included 664 RRMS patients: 315 in the fingolimod, 232 in the DMF and 117 in the teriflunomide group. The baseline data of the 664 patients are summarized in Table 1 Thirty-seven patients switched from fingolimod (7.2%) to natalizumab (n = 18), to DMF (n = 10), to alemtuzumab (n = 7) or to teriflunomide (n = 2). Twenty patients switched from DMF (4.7%) to fingolimod (n = 8), to natalizumab (n = 8), to alemtuzumab (n = 2) or to teriflunomide (n = 2) and 23 patients from teriflunomide (10.4%)
to fingolimod (n = 10), to natalizumab (n = 7) or to DMF (n = 6).
The reasons for interrupting fingolimod were mainly adverse events (AEs) (n = 51), patient's wishes (patient's decision) (n = 48) and disease progression (clinical and/or radiological activity) (n = 40), for DMF patients' wishes (n = 37), AEs (n = 22) and disease progression (n = 18). The main reasons for interrupting teriflunomide were patients' wishes (n = 20), followed by disease progression (n = 19) and AEs (n = 15). Pregnancy or the wishes to conceive were documented in either nine patients in the fingolimod and DMF group and in one patient in the teriflunomide cohort. The treating neurologist could name several reasons per patient.
The ARR for patients staying on treatment over the whole obser- This early treatment effect under fingolimod was already shown in F I G U R E 2 Cumulative probability for disability progression sustained for 12 (a) and 24 weeks (b) and disability regression sustained for 12 (c) and 24 weeks (d) within the first 12 months RRMS treatment with fingolimod, dimethyl fumarate or teriflunomide. DMF, dimethyl fumarate; FTY, fingolimod; TERI, teriflunomide other studies, 18, 19 and the low ARR under teriflunomide in the first three months of treatment is mainly attributed to the lower ARR of the teriflunomide cohort at baseline.
The hazard ratio for relapse probability in the 12 months continuous treatment period was 1.20 for fingolimod vs DMF and 0.95 for teriflunomide vs DMF, without significant differences (P = 0.540
and P = 0.876). In addition, we found no difference analysing EDSS change, EDSS progression or regression, except regarding reduced sustained EDSS progression for 12 weeks concerning DMF vs fingolimod (P = 0.028).
The different indications resulted in differences in the cohorts at baseline. In particular, the teriflunomide group was older and less likely to have had a relapse in the prior 12 months. Over 90% of the fingolimod patients had received prior treatment as compared to only 58% of the DMF and 68% of the teriflunomide cohort. In contrast, DMF patients were younger and less disabled with a shorter disease duration. Being fully aware of the documented differences, we used inverse probability weighting to control these differences.
A further limitation concerns the observation period over 12 months in terms of efficacy analysis. In comparison with two studies with an observation period of 24 months and another study with an observation period of 12 months, we found similar relapse rates. [10] [11] [12] There were no substantial differences regarding the 12 and 24 months analyses. The mean time to discontinuation ranged from 4 to 10 months indicating highest disease activity within the first 12 months.
Our results are within the range of the findings of other observational studies using propensity scores for matching baselines covariates. Observational studies, like our study, miss the two most important parts of randomized clinical trials, that is randomization and blinding. However, it is meanwhile to some extent agreed that propensity scoring can compensate to a certain degree for the lack of randomization and may control for known and recorded confounding covariates. 21 In everyday clinical practice, however, patients' and neurologists' attitudes towards the choice of treatment may be influenced by different non-recordable clinical or subclinical conditions that also may influence future disease activity.
The lack of blinding here may not have the same effect as in placebo-controlled trials, because our study was a post hoc study, which was not planned at the time of the prospective data collection, and therefore, patients and treating neurologists could not be aware that their medical recordings would be used for analysis.
The most important limitation of our study is the missing MRI data during the observational period. MRI data were only available at baseline before starting treatment with fingolimod, DMF and teriflunomide and were included as an independent variable for propensity score matching.
In conclusion, we found no difference analysing ARR, probability for experiencing a relapse, EDSS change, treatment interruption, EDSS progression and EDSS regression, except regarding reduced sustained EDSS progression for 12 weeks concerning DMF vs fingolimod (P = 0.028).
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